Due to the global nature of our operations, portions of our revenue and operating expense are recorded in currencies other than the U.S. dollar. The value of revenue and operating expense measured in U.S. dollars is therefore subject to changes in foreign currency exchange rates. We enter into foreign currency forward contracts and foreign currency options with financial institutions with the primary objective to mitigate the impact of foreign currency exchange rate fluctuations on our international revenue and operating expense.

Foreign currency forward contracts and foreign currency options in effect as of September 30, 2022 and December 31, 2021, had durations of 1 to 15 months. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the

effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenue when the sale of product in the currency being hedged is recognized and in operating expense when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income (loss) and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that have been impacted by the hedged item.


	Notional Amount
(In millions)	As of September 30, 2022		As of December 31, 2021
Euro	$	1,089.2	$	1,828.0
British pound	43.5		166.2
Swiss franc	37.8		—
Japanese yen	23.5		72.7
Canadian dollar	14.7		59.9
Total foreign currency forward contracts	$	1,208.7	$	2,126.8

We expect the net unrealized gains of approximately $144.3 million to be settled over the next 15 months, of which approximately $142.6 million of these net unrealized gains are expected to be settled over the next 12 months, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties’ credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of September 30, 2022 and December 31, 2021, credit risk did not materially change the fair value of our foreign currency forward contracts.


For the Three Months Ended September 30,
Net Gains/(Losses) Reclassified from AOCI into Operating Income (in millions)					Net Gains/(Losses) Recognized in Operating Income (in millions)
Location	2022		2021		Location	2022		2021
Revenue	$	77.7	$	(14.9)	Revenue	$	6.6	$	(0.7)
Operating expense	(0.8)		(0.3)		Operating expense	(0.1)		—

For the Nine Months Ended September 30,
Net Gains/(Losses) Reclassified from AOCI into Operating Income (in millions)					Net Gains/(Losses) Recognized in Operating Income (in millions)
Location	2022		2021		Location	2022		2021
Revenue	$	143.2	$	(68.7)	Revenue	$	(0.8)	$	(4.5)
Operating expense	(3.5)		(0.3)		Operating expense	(0.4)		(0.4)

In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately 5.0% to approximately 49.9%. The share purchase transaction was completed in November 2018 and, upon closing,

In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we entered into foreign currency forward contracts. These contracts were designated as net investment hedges. In April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics and closed these foreign currency forward contracts. Upon completing this sale, the cumulative gains on our net investment hedges of $57.0 million were reclassified from accumulated other comprehensive income (loss) and reflected within the total pre-tax gain recognized from the sale, which was recorded in other (income) expense, net in our condensed consolidated statements of income. For additional information on the sale of our equity interest in Samsung Bioepis, please read Note 2, Dispositions, to these condensed consolidated financial statements.

Prior to the sale of our 49.9% equity interest in Samsung Bioepis, we recognized changes in the spot exchange rate of these foreign currency forward contracts in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of $10.6 million as of December 31, 2021. We excluded fair value changes related to the forward rate from our hedging relationship and amortized the forward points in other (income) expense, net in our condensed consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected net losses of $3.6 million as of December 31, 2021.


For the Three Months Ended September 30,
Net Gains/(Losses) Recognized in Other Comprehensive Income (Effective Portion) (in millions)					Net Gains/(Losses) Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) (in millions)					Net Gains/(Losses) Recognized in Net Income (Amounts Excluded from Effectiveness Testing) (in millions)
Location	2022		2021		Location	2022		2021		Location	2022		2021
Gains (losses) on net investment hedges(1)	$	—	$	24.9	Gains (losses) on net investment hedges(1)	$	—	$	—	Other (income) expense(1)	$	—	$	—

For the Nine Months Ended September 30,
Net Gains/(Losses) Recognized in Other Comprehensive Income (Effective Portion) (in millions)					Net Gains/(Losses) Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) (in millions)					Net Gains/(Losses) Recognized in Net Income (Amounts Excluded from Effectiveness Testing) (in millions)
Location	2022		2021		Location	2022		2021		Location	2022		2021
Gains (losses) on net investment hedges(1)	$	20.4	$	46.1	Gains (losses) on net investment hedges(1)	$	(3.2)	$	(1.1)	Other (income) expense(1)	$	(4.6)	$	0.1

(1) Beginning in the second quarter of 2022 we no longer hold net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read Note 2, Dispositions, to these condensed consolidated financial statements.

We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.

The aggregate notional amount of these outstanding foreign currency forward contracts was $1,285.4 million and $1,268.0 million as of September 30, 2022 and December 31, 2021, respectively. Net losses of $36.5 million and $85.8 million related to these contracts were recorded as a component of other (income) expense, net for the three and nine months ended September 30, 2022, respectively, compared to net losses of $13.5 million and $26.1 million, respectively, in the prior year comparative periods.

While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.


(In millions)	Balance Sheet Location	As of September 30, 2022		As of December 31, 2021
Cash Flow Hedging Instruments:
Asset derivative instruments	Other current assets	$	158.2	$	66.2
	Investments and other assets	5.0		5.5
Liability derivative instruments	Accrued expense and other	2.6		6.6


Net Investment Hedging Instruments:(1)
Asset derivative instruments	Other current assets	21.4		4.1






Other Derivative Instruments:
Asset derivative instruments	Other current assets	11.3		5.1
Liability derivative instruments	Accrued expense and other	20.2		4.2

(1) Beginning in the second quarter of 2022 we no longer hold net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. Amount represents unsettled balance of our closed net investment hedges. For additional information on the sale of our equity interest in Samsung Bioepis, please read Note 2, Dispositions, to these condensed consolidated financial statements.